Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.

A Gene Expression Signature to Select Hepatocellular Carcinoma Patients for Liver Transplantation

Open access
Pinto-Marques, Hugo, Cardoso, Joana, Silva, Sílvia, Neto, João L., Gonçalves-Reis, Maria, Proença, Daniela, Mesquita, Marta, Manso, André, Carapeta, Sara, Sobral, Mafalda, Figueiredo, Antonio, Rodrigues, Clara, Milheiro, Adelaide, Carvalho, Ana, Perdigoto, Rui, Barroso, Eduardo, Pereira-Leal, José B. · 2022 · Annals of Surgery

Abstract

Objective: To propose a new decision algorithm combining biomarkers measured in a tumor biopsy with clinical variables, to predict recurrence after liver transplantation (LT). Background: Liver cancer is one of the most frequent causes of cancer-related mortality. LT is the best treatment for hepatocellular carcinoma (HCC) patients but the scarcity of organs makes patient selection a critical step. In addition, clinical criteria widely applied in patient eligibility decisions miss potentially curable patients while selecting patients that relapse after transplantation. Methods: A literature systematic review singled out candidate biomarkers whose RNA levels were assessed by quantitative PCR in tumor tissue from 138 HCC patients submitted to LT (>5 years follow up, 32% beyond Milan criteria). The resulting 4 gene signature was combined with clinical variables to develop a decision algorithm using machine learning approaches. The method was named HepatoPredict. Results: HepatoPredict identifies 99% disease-free patients (>5 year) from a retrospective cohort, including many outside clinical criteria (16%–24%), thus reducing the false negative rate. This increased sensitivity is accompanied by an increased positive predictive value (88.5%–94.4%) without any loss of long-term overall survival or recurrence rates for patients deemed eligible by HepatoPredict; those deemed ineligible display marked reduction of survival and increased recurrence in the short and long term. Conclusions: HepatoPredict outperforms conventional clinical-pathologic selection criteria (Milan, UCSF), providing superior prognostic information. Accurately identifying which patients most likely benefit from LT enables an objective stratification of waiting lists and information-based allocation of optimal versus suboptimal organs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/sla.0000000000005637

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 HepatoPredict 2-step algorithm. A, First algorithm identifies good prognosis patients with a PPV=94% (Class I); the remaining patients go through a second algorithm that identifies further good prognosis patients at a PPV=88,5% (Class II). For the remaining patients HepatoPredict does not predict any benefit in liver transplantation. B, Patients proposed for transplantation and their outcome after 5 years according to HepatoPredict Class I and Class I+II versus Milan Criteria (Milan) or UCSF Criteria (UCSF); a positive outcome (No relapse) represented in light blue versus a negative outcome (Relapsed) in red. B, Overlap of transplanted patients that did not relapse (darker blue) with a positive prognosis according to HepatoPredict Class I or Class I+II (light blue), Milan or UCSF criteria (light gray).
FIGURE 1 HepatoPredict 2-step algorithm. A, First algorithm identifies good prognosis patients with a PPV=94% (Class I); the remaining patients go through a second algorithm that identifies further good prognosis patients at a PPV=88,5% (Class II). For the remaining patients HepatoPredict does not predict any benefit in liver transplantation. B, Patients proposed for transplantation and their outcome after 5 years according to HepatoPredict Class I and Class I+II versus Milan Criteria (Milan) or UCSF Criteria (UCSF); a positive outcome (No relapse) represented in light blue versus a negative outcome (Relapsed) in red. B, Overlap of transplanted patients that did not relapse (darker blue) with a positive prognosis according to HepatoPredict Class I or Class I+II (light blue), Milan or UCSF criteria (light gray).CC BY-NC-ND · PubMed Central
FIGURE 2 Recurrence curves of transplanted liver cancer patients at 5 years (60 months), according to HepatoPredict Class I+II (blue lines) versus Milan or UCSF Criteria (gray lines, left and right columns, respectively). Cumulative recurrence curves for the entire population of transplanted patients compared with Milan (A) and UCSF (B) criteria, for the subpopulations of patients originally classified outside Milan (C) and UCSF (D) criteria, and for the subpopulations of patients originally classified within (E) Milan and (F) UCSF criteria.
FIGURE 2 Recurrence curves of transplanted liver cancer patients at 5 years (60 months), according to HepatoPredict Class I+II (blue lines) versus Milan or UCSF Criteria (gray lines, left and right columns, respectively). Cumulative recurrence curves for the entire population of transplanted patients compared with Milan (A) and UCSF (B) criteria, for the subpopulations of patients originally classified outside Milan (C) and UCSF (D) criteria, and for the subpopulations of patients originally classified within (E) Milan and (F) UCSF criteria.CC BY-NC-ND · PubMed Central
FIGURE 3 Overall survival curves of transplanted liver cancer patients at ~15 years according to the original Milan or UCSF selection criteria (left and right columns, respectively). Cumulative overall survival curves for the entire population of transplanted patients divided according to (A) Milan or (B) UCSF criteria. The curves represent the overall survival prediction according to HepatoPredict Class I+II (blue lines) versus Milan or UCSF Criteria (gray lines).
FIGURE 3 Overall survival curves of transplanted liver cancer patients at ~15 years according to the original Milan or UCSF selection criteria (left and right columns, respectively). Cumulative overall survival curves for the entire population of transplanted patients divided according to (A) Milan or (B) UCSF criteria. The curves represent the overall survival prediction according to HepatoPredict Class I+II (blue lines) versus Milan or UCSF Criteria (gray lines).CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 62 references

Research works printed but not linked: 1

  1. Carr, 2018, HCC with low- and normal-serum alpha-fetoprotein levels, Clin Pract (Lond), 15, 453

Cited by

See all 20

Metadata

Authors
Pinto-Marques, H., Cardoso, J., Silva, S., Neto, J. L., Gonçalves-Reis, M., Proença, D., Mesquita, M., Manso, A., Carapeta, S., Sobral, M., Figueiredo, A., Rodrigues, C., Milheiro, A., Carvalho, A., Perdigoto, R., Barroso, E., & Pereira-Leal, J. B.
Affiliations
  • Hepato-Biliary-Pancreatic and Transplantation Centre, Curry Cabral Hospital, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal
  • Ophiomics—Precision Medicine, Lisbon, Portugal
  • Unidade Local de Saúde de São José (PT)
  • Instituto Gulbenkian de Ciência (PT)
Corresponding author
  • Silva, Sílvia
  • Sobral, Mafalda
  • Rodrigues, Clara
  • Milheiro, Adelaide
  • Carvalho, Ana
  • Perdigoto, Rui
  • Barroso, Eduardo
Venue
Annals of Surgery
Published
2022-08-01
Volume
276
Issue
5
Pages
868-874
ISSN
0003-4932 (ISSN-L)
OpenAlex
W4289525814
Cited by
20
References
62
Citations by year
2026: 2 · 2025: 10 · 2024: 5 · 2023: 3
FWCI
0.77
Type
journal article
Language
en
Open access
Locations
  • Annals of Surgery (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, other-oa)
Funders
HORIZON EUROPE European Innovation Council (946364)
Topics
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
  • Health Sciences › Medicine › Surgery › Organ Transplantation Techniques and Outcomes
Keywords
hepatocellular carcinoma, liver transplantation, patient selection, gene expression signatures, tumor recurrence prediction, biomarkers, decision-making algorithm, Milan criteria, UCSF criteria, organ allocation, prognostic model
MeSH terms
Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Neoplasm Recurrence, Local, Retrospective Studies, Risk Factors, RNA, Liver Transplantation, Patient Selection, Transcriptome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Gene Expression Signature to Select Hepatocellular Carcinoma Patients for Liver Transplantation. https://app.cochat.ai/papers/10.1097/sla.0000000000005637
The paper
Pinto-Marques, H., Cardoso, J., Silva, S., Neto, J. L., Gonçalves-Reis, M., Proença, D., Mesquita, M., Manso, A., Carapeta, S., Sobral, M., Figueiredo, A., Rodrigues, C., Milheiro, A., Carvalho, A., Perdigoto, R., Barroso, E., & Pereira-Leal, J. B. (2022). A Gene Expression Signature to Select Hepatocellular Carcinoma Patients for Liver Transplantation. Annals of Surgery. https://doi.org/10.1097/sla.0000000000005637

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.